Prolotherapy, Joint Sclerotherapy, and Ligamentous Injections with Sclerosing Agents | CMS Coverage Update

Summary: The Centers for Medicare & Medicaid Services modified its coverage policy for prolotherapy, joint sclerotherapy, and ligamentous injections with sclerosing agents, effective May 15, 2026. Here's what billing teams need to know before that date.

CMS has updated its position on prolotherapy and related sclerosing injection procedures. This coverage policy affects orthopedic, pain management, and musculoskeletal billing teams who submit claims for joint injections and ligament treatments under Medicare. The policy does not list specific CPT or HCPCS codes in the available data — we'll address what that means for your charge capture below.

Quick-Reference Table

CMS Prolotherapy Coverage Criteria and Medical Necessity Requirements 2026

The CMS prolotherapy and joint sclerotherapy coverage policy has a long history — and not a favorable one for providers. Medicare has consistently treated prolotherapy and ligamentous injections with sclerosing agents as procedures lacking sufficient evidence to support routine reimbursement. The May 15, 2026, modification signals that CMS has revisited this position, though the direction of that revision matters enormously for your billing team.

Whether Medicare covers prolotherapy is a question your billing team has almost certainly heard from patients. The short answer, historically, has been no. CMS has classified prolotherapy — the injection of irritant or sclerosing solutions into joints, tendons, or ligaments to stimulate tissue repair — as not meeting medical necessity standards under Medicare. Joint sclerotherapy follows the same logic.

This updated coverage policy requires your billing team to understand exactly what changed in the May 15, 2026, version. The available policy data does not include the full revised text or specific CPT and HCPCS codes. That gap is a problem, and you should pull the complete policy document directly from CMS before the effective date.

Prior authorization requirements for prolotherapy under Medicare have not traditionally been the primary hurdle — denial at the coverage determination level has been. If the modification introduces any prior authorization pathway for specific indications, that would be a meaningful shift. Contact your Medicare Administrative Contractor to confirm whether any MAC-level local coverage determination applies to your jurisdiction alongside this national update.

Medical necessity documentation is the core battleground for these claims. If any indication now qualifies for coverage, your clinical staff need to know exactly what documentation CMS requires to support that medical necessity determination. Generic chart notes won't survive a post-payment audit.

CMS Prolotherapy Exclusions and Non-Covered Indications

Historically, CMS has treated prolotherapy, joint sclerotherapy, and ligamentous injections with sclerosing agents as experimental or investigational procedures. The agency's position has been that the clinical evidence does not support a finding that these procedures improve health outcomes for Medicare beneficiaries.

That means claim denial has been the default outcome for these procedures — not a risk, but a near-certainty without a covered indication. If the May 15, 2026, modification narrows the exclusion rather than eliminating it, your billing team needs to map every procedure in your charge capture against the updated criteria.

The real issue here is that "modified" can mean almost anything. A modification could loosen coverage criteria, tighten them, or restructure how indications are documented. Do not assume this modification expands coverage without reading the updated policy text. Assumptions in either direction will cost you — either in denied claims or in missed reimbursement opportunities.

If you submit claims for any variant of sclerosing injections — dextrose prolotherapy, sodium morrhuate injections, phenol-glycerine-glucose solutions — review each one against the updated policy before May 15, 2026.

Coverage Indications at a Glance

The available policy data does not provide indication-level criteria with specific coverage determinations. The table below reflects what CMS's historical position has been on these procedures, combined with the context of this modification. Pull the full updated policy text to confirm current status before May 15, 2026.

CMS Prolotherapy Billing Guidelines and Action Items 2026

These billing guidelines apply to any practice that submits Medicare claims for prolotherapy, joint sclerotherapy, or ligamentous injections with sclerosing agents. Act on these before May 15, 2026.

CPT, HCPCS, and ICD-10 Codes for Prolotherapy and Joint Sclerotherapy Under This Policy

A Note on Code Availability

The policy data available for this modification does not include specific CPT, HCPCS, or ICD-10 codes. This is not an omission on our part — the source data does not list them. Do not rely on any third-party list of codes for this policy without confirming against the actual CMS policy document.

Prolotherapy billing typically involves musculoskeletal injection codes, but the specific codes covered, excluded, or newly addressed under this modification must come from the official CMS policy text. Using the wrong codes — even codes that seem clinically appropriate — creates claim denial exposure and potential compliance risk.

What to Do Instead

Pull the full policy from CMS and extract the affected codes directly. Cross-reference those codes against your charge master. If you need help mapping CPT codes to the updated coverage criteria, your billing consultant or a coding specialist with musculoskeletal expertise should lead that review.

PayerPolicy tracks code-level detail as it becomes available. When the full policy text is indexed, the code tables will be updated at app.payerpolicy.org/p/cms/15-v1.: https://app.payerpolicy.org/p/cms/15-v1.